764659-69-0

Basic information

• Product Name: tert-butyl [(1S,2S)-2-(benzyloxy)cyclohexyl]carbamate
• Synonyms: tert-butyl [(1S,2S)-2-(benzyloxy)cyclohexyl]carbamate
• CAS NO: 764659-69-0
• Molecular Weight: 305.417
• Mol File: 764659-69-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: tert-butyl [(1S,2S)-2-(benzyloxy)cyclohexyl]carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl [(1S,2S)-2-(benzyloxy)cyclohexyl]carbamate(764659-69-0)
• EPA Substance Registry System: tert-butyl [(1S,2S)-2-(benzyloxy)cyclohexyl]carbamate(764659-69-0)

Safety Data

• Hazardous Substances Data: 764659-69-0(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 216394-07-9 1-(S)-trans-(S)-2-phenylmethoxycyclohexylamine 

Downstream Products

• 121282-70-0 (1S,2S)-2-tert-Butoxycarbonylamino-1-cyclohexanol 
• 365996-28-7 (1S,2S)-2-(tert-butoxycarbonylamino)cyclohexyl methanesulfonate 
• 365996-30-1 tert-butyl ((1S,2R)-2-aminocyclohexyl)carbamate 
• 365996-29-8 (1R,2S)-2-(N-tert-butyloxycarbonylamino)-1-azidocyclohexane 
• 764659-50-9 (1R, 2S)-3-chloro-1H-indole-6-carboxylic acid (2-amino-cyclohexyl)-amide 
• 764659-49-6 (1S,2R)-{2-[(3-chloro-1H-indole-6-carbonyl)-amino]-cyclohexyl}-carbamic acid tert-butyl ester 
• 950677-99-3 C₁₁H₁₅ClN₂OS 

Relevant articles and documents

Discovery and structure-activity relationships of 4-aminoquinazoline derivatives, a novel class of opioid receptor like-1 (ORL1) antagonists

Synthesis and structure-activity relationship studies of a series of 4-aminoquinazoline derivatives led to the identification of (1R,2S)-17, N-[(1R,2S)-2-({2-[(4-chlorophenyl)carbonyl]amino-6-methylquinazolin-4-yl}amino)cyclohexyl]guanidine dihydrochloride, as a highly potent ORL1 antagonist with up to 3000-fold selectivity over the μ, δ, and κ opioid receptors. Molecular modeling clarified the structural factors contributing to the high affinity and selectivity of (1R,2S)-17.

SULFUR COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE

The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.